Desai et al.3 focused on a population of patients with pulmonary arterial hypertension and compared users of PDE-5 inhibitors with users of endothelin receptor antagonists, whereas Fang et al.5 compared users of sildenafil versus nonusers as well as comparing with users taking medications for cardiometabolic disease. Here, PDE5A is linked to pulmonary arterial hypertension.